• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>La Presse medicale >Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues
【24h】

Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues

机译：非小细胞肺癌的预后和预测性生物标志物。从条件注册到肺癌的常规分子作图：方法学问题

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Targeted therapies booming and new efficacious cytotoxics emergence in non-small cell lung cancers (NSCLC) deeply changed prognosis in some subsets of patients experiencing long survival. A priori identification (at time of diagnosis) of patients the most beneficiating from those often costly therapies is the new issue in thoracic oncology. For EGFR tyosine kinase inhibitors (TKI), molecular targeting relies on EGFR mutations diagnosis, that led to the first conditioned molecular-based registration for a drug in thoracic oncology, that was made easier in France by French NCI huge effort to sponsor the 28 regional molecular biology platforms. For the majority of classical cytotoxics used in adjuvant treatment after lung cancer surgical resection, biomarkers relying on immunohistochemistry still need further prospective validation steps before routine use. Prospective validation studies aimed to evaluate the ability of those biomarkers to predict not only response to therapy, but also survival with a specific treatment (predictive value), need large phase 3 trials with centralized biomarker analyses and rigorous statistical methods. French Intergroup (IFCT) has initiated such studies that will help to validate new biomarkers that we may use routinely in lung cancer in near future.
机译：非小细胞肺癌（NSCLC）中针对性疗法的兴起和新的有效细胞毒素的出现深刻改变了一些长期生存患者的预后。从那些经常昂贵的治疗中受益最大的患者（在诊断时）的先验鉴定是胸部肿瘤学的新课题。对于EGFR酪氨酸激酶抑制剂（TKI），分子靶向依赖EGFR突变诊断，这导致了第一个基于条件的基于分子的胸腔肿瘤药物注册，法国NCI大力资助了28个地区性研究，使在法国的注册更加容易分子生物学平台。对于肺癌手术切除后辅助治疗中使用的大多数经典细胞毒素，依赖于免疫组织化学的生物标志物在常规使用前仍需要进一步的前瞻性验证步骤。前瞻性验证研究旨在评估那些生物标记物不仅预测治疗反应的能力，而且还预测特定疗法的生存率（预测值），因此需要大型3期试验，需要集中的生物标记物分析和严格的统计方法。法国团体（IFCT）已启动此类研究，这将有助于验证我们在不久的将来可能在肺癌中常规使用的新生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号